Amarin Announces Notification of Patent Allowance for U.S. Application 13/610,247 Related to Vascepa(R) and FDA Approved MARINE

Amarin Announces Notification of Patent Allowance for U.S. Application
13/610,247 Related to Vascepa(R) and FDA Approved MARINE Indication

Strengthens Positioning of Vascepa for Exclusivity Into 2030

BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 26, 2012 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the United States Patent and
Trademark Office (USPTO) has published notification of Notice of Allowance for
U.S. Patent Application Serial Number 13/610,247. This application includes
claims intended to protect the Vascepa^® (icosapent ethyl) indication approved
in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's
MARINE clinical trial results.

The '247 application is a continuation of Amarin's U.S. Patent Number
8,293,728 (formerly, the '153 application) and broadens the '728 claims by
covering the use of Vascepa with and without other lipid lowering agents, such
as statins. The '247 application claims gauge drug effects against a subject's
own baseline and, alternatively, on a patient population basis. On November
19, 2012, Amarin announced notification of a Notice of Allowance for U.S.
Patent Application Serial Number 13/608,775 which is also a continuation of
the '728 application and also broadens the '728 claims by covering the use of
Vascepa with and without other lipid lowering agents, but gauges Vascepa
effects against placebo control.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. After issuance, Amarin plans to list
this patent in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.

"This Notice of Allowance builds on the recent allowance for U.S. Patent
Application Serial Number 13/608,775, both of which cover the use of Vascepa
with or without the use of lipid altering agents, such as statins. This is
significant in that it broadens our currently issued MARINE method of use
claims," stated Joseph Zakrzewski, Chairman and CEO of Amarin. "The issuance
of this Notice of Allowance represents yet another significant step toward
Amarin's goal of protecting the commercial potential of Vascepa to beyond 2030
through patent protection, regulatory exclusivity and trade secrets and by
taking advantage of manufacturing barriers to entry."

The 13/610,247 Notice of Allowance has not yet been posted on the USPTO public
PAIR website. Amarin has posted this Notice of Allowance and related claims in
the Press Release section of its corporate website.

This application is part of an expanding patent portfolio for Amarin with 10
patent applications now either issued or allowed with the USPTO and over 30
additional applications pending in the United States. Amarin is also pursuing
patent applications related to Vascepa in multiple jurisdictions outside the
United States, including the application for Amarin's MARINE method of use
patent in Europe for which Amarin has announced receipt of an Intention to
Grant letter.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patent would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patent,
Amarin's plan to list the patent, when issued, in FDA's Orange Book, Amarin's
plan to protect the commercial potential of Vascepa, and the future status of
pending patent applications. These forward-looking statements are not promises
or guarantees and involve substantial risks and uncertainties. Among the
factors that could cause actual results to differ materially from those
described or projected herein include the following: events that could
interfere with the issuance of a patent, or once issued, the continued
validity or enforceability of a patent; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trials and related regulatory approvals. A
further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Amarin undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

CONTACT: Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.